Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asher Salmon

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
EJNMMI Physics|December 12, 2018
Predictive power of the post-treatment scans after the initial or first two courses of [<sup>177</sup>Lu]-DOTA-TATEAlexandre Chicheportiche, Simona Grozinsky-Glasberg, David J Gross, et al.
Oncotarget|December 24, 2015
Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer modelTamar Zahavi, Tali Lanton, Mali Salmon Divon, et al.
Endocrine-Related Cancer|May 27, 2006
The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-RDavid J Gross, Gabriel Munter, Menachem Bitan, et al.
Molecular Imaging and Biology|July 24, 2010
68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®)Yodphat Krausz, Nanette Freedman, Rina Rubinstein, et al.
Clinical Nuclear Medicine|December 14, 2011
Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patternsYodphat Krausz, Rina Rubinstein, Liat Appelbaum, et al.
Antimicrobial Resistance and Infection Control|November 3, 2018
Beyond the hospital infection control guidelines: a qualitative study using positive deviance to characterize gray areas and to achieve efficacy and clarity in the prevention of healthcare-associated infectionsAnat Gesser-Edelsburg, Ricky Cohen, Adva Mir Halavi, et al.
NPJ Breast Cancer|May 29, 2021
Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancerTamar Zahavi, Mali Salmon-Divon, Roberto Salgado, et al.
International Journal of Cancer|January 7, 2020
Reactive stroma and trastuzumab resistance in HER2-positive early breast cancerAmir Sonnenblick, Mali Salmon-Divon, Roberto Salgado, et al.
International Journal of Oncology|December 6, 2017
p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trialAmir Sonnenblick, Roberto Salgado, Sylvain Brohée, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
EJNMMI Physics|December 12, 2018
Predictive power of the post-treatment scans after the initial or first two courses of [<sup>177</sup>Lu]-DOTA-TATEAlexandre Chicheportiche, Simona Grozinsky-Glasberg, David J Gross, et al.
Oncotarget|December 24, 2015
Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer modelTamar Zahavi, Tali Lanton, Mali Salmon Divon, et al.
Endocrine-Related Cancer|May 27, 2006
The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-RDavid J Gross, Gabriel Munter, Menachem Bitan, et al.
Molecular Imaging and Biology|July 24, 2010
68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ¹¹¹In-DTPA-octreotide (OctreoScan®)Yodphat Krausz, Nanette Freedman, Rina Rubinstein, et al.
Clinical Nuclear Medicine|December 14, 2011
Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patternsYodphat Krausz, Rina Rubinstein, Liat Appelbaum, et al.
Antimicrobial Resistance and Infection Control|November 3, 2018
Beyond the hospital infection control guidelines: a qualitative study using positive deviance to characterize gray areas and to achieve efficacy and clarity in the prevention of healthcare-associated infectionsAnat Gesser-Edelsburg, Ricky Cohen, Adva Mir Halavi, et al.
NPJ Breast Cancer|May 29, 2021
Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancerTamar Zahavi, Mali Salmon-Divon, Roberto Salgado, et al.
International Journal of Cancer|January 7, 2020
Reactive stroma and trastuzumab resistance in HER2-positive early breast cancerAmir Sonnenblick, Mali Salmon-Divon, Roberto Salgado, et al.
International Journal of Oncology|December 6, 2017
p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trialAmir Sonnenblick, Roberto Salgado, Sylvain Brohée, et al.
Pageof 2